All articles tagged: Malignant neoplasm of unspecified part of left bronchus or lung (C34.92)

Chemoradiation with an adaptive stereotactic ablative radiotherapy (SABR) boost is safe and effective for patients with locally advanced, unresectable non–small cell lung cancer (NSCLC), according to a study published online Jan. 11 in JAMA Oncology.Trudy C. Wu, M.D., from the University of California in Los Angeles, and colleagues exa

The NPR article reports elevated levels of the carcinogen chromium-6 in wildfire ash, potentially posing health risks like lung cancer due to inhalation. Researchers call for further investigation and protective measures in affected areas.

For patients with metastatic non-small cell lung cancer (NSCLC) receiving immunotherapy, outcomes are similar across racial and ethnic groups, but ECOG performance status (PS) is associated with survival, according to a study published online Dec. 11 in the Journal of the National Comprehensive Cancer Network.Matthew Lee, M.D., M.P.H

The annual meeting of the Radiological Society of North America was held from Nov. 26 to 30 in Chicago, drawing nearly 25,000 participants, including radiologists, radiation oncologists, physicists in medicine, radiologic technologists, and other health care professionals. The conference featured scientific papers from a number of subspecialtie

For an expanded International-Early Lung Cancer Action Program (I-ELCAP) cohort who underwent annual low-dose computed tomography (CT) screening, the 10-year lung cancer-specific survival of 80 percent reported in 2006 has persisted at 20 years, according to a study published online Nov. 7 in Radiology.Claudia I. Henschke, Ph.D., M.D.,

For patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC), osimertinib with chemotherapy leads to significantly longer progression-free survival (PFS) compared with osimertinib alone, according to a study published online Nov. 8 in the New England Journal of Medicine.David Planchard, M.D., Ph.D., from Institu

In a guideline update issued by the American Cancer Society and published online Nov. 1 in CA: A Cancer Journal for Clinicians, the authors recommend increasing eligibility for lung cancer screening (LCS).Andrew M.D. Wolf, M.D., from the University of Virginia School of Medicine in Charlottesville, and colleagues updated the American C

A study by the Ontario Institute for Cancer Research links tobacco smoking to DNA mutations that disrupt cancer-fighting proteins, increasing cancer risk and complicating treatment. The more one smokes, the more mutations occur, particularly in lung cancer, highlighting smoking's severe impact on cellular health and cancer development.

The American Cancer Society has updated its lung cancer screening guidelines to include adults aged 50-80 with a significant smoking history, regardless of how long ago they quit. This expansion could prevent 21% more lung cancer deaths and is aimed at improving early detection, especially in high-risk communities.